In our previous study, clinically applied JX-594 conferred tumor selectivity via viral thymidine kinase (vTK) inactivation because vaccinia virus has evolved to replicate in EGFR pathway-activated cells, which are usually cancer cells with high cellular TK levels [10, 12–14]. This evidence concerns the gene EGFR and neoplasm.